Patents by Inventor Hideo Takasu

Hideo Takasu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION USE OF WT1 ANTIGEN PEPTIDE AND IMMUNOMODULATOR
    Publication number: 20180140691
    Abstract: The invention relates to a combination use of a WT1 antigen peptide or a pharmaceutically acceptable salt thereof and an immunomodulator for treating or preventing cancer.
    Type: Application
    Filed: May 19, 2016
    Publication date: May 24, 2018
    Applicants: Sumitomo Dainippon Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.
    Inventors: Hideo TAKASU, Megumi NAKAMURA, Masashi GOTO, Natsuko SUGINOBE
  • Dimerized peptide
    Patent number: 8242084
    Abstract: The present invention provides a novel tumor antigen peptide and its cancer vaccine, specifically, a peptide dimer wherein two peptide monomers consisting of 7-30 amino acids including at least one cysteine residue and being capable of producing a tumor antigen peptide are bound each other through a disulfide bond.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: August 14, 2012
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.
    Inventors: Haruo Sugiyama, Hideo Takasu, Fumio Samizo
  • DIMERIZED PEPTIDE
    Publication number: 20100292164
    Abstract: The present invention provides a novel tumor antigen peptide and its cancer vaccine, specifically, a peptide dimer wherein two peptide monomers consisting of 7-30 amino acids including at least one cysteine residue and being capable of producing a tumor antigen peptide are bound each other through a disulfide bond.
    Type: Application
    Filed: June 7, 2010
    Publication date: November 18, 2010
    Applicant: HARUO SUGIYAMA
    Inventors: Haruo SUGIYAMA, Hideo Takasu, Fumio Samizo
  • HLA-A24-restricted cancer antigen peptides
    Patent number: 7666985
    Abstract: HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: February 23, 2010
    Assignees: International Institute of Cancer Immunology, Inc., Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Haruo Sugiyama, Masashi Gotoh, Hideo Takasu
  • HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES
    Publication number: 20090099090
    Abstract: HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients.
    Type: Application
    Filed: June 19, 2008
    Publication date: April 16, 2009
    Applicants: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED, CHUGAI SEIYAKU KABUSHIKI KAISHA, International Institute of Cancer Immunology, Inc, Dainippon Sumitomo Pharma Company, Limited
    Inventors: Haruo Sugiyama, Masashi Gotoh, Hideo Takasu
  • HLA-A24-restricted cancer antigen peptides
    Patent number: 7420034
    Abstract: HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: September 2, 2008
    Assignees: Dainippon Sumitomo Pharma Co., Ltd., Chugai Seiyaku Kabushiki Kaisha, International Institute of Cancer Immunology, Inc.
    Inventors: Haruo Sugiyama, Masashi Gotoh, Hideo Takasu
  • WT1 substitution peptides
    Patent number: 7378384
    Abstract: Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. Peptides which comprise an amino acid sequence of the formula: X-Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4) wherein X represents Ser, Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe, or Asn, and Y represents Tyr or Met, and which has an activity to induce CTLs, polynucleotides encoding said peptides, cancer vaccines which comprise those peptides or polynucleotides as an active ingredient, and the like are disclosed.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: May 27, 2008
    Assignees: International Institute of Cancer Immunology, Inc., Chugai Seiyaku Kabushiki Kaisha, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Haruo Sugiyama, Masashi Gotoh, Hideo Takasu, Fumio Samizo, Naoto Kusunose, Masashi Nakatsuka
  • Hla-a24-restricted cancer antigen peptides
    Publication number: 20070082860
    Abstract: HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients.
    Type: Application
    Filed: June 12, 2003
    Publication date: April 12, 2007
    Inventors: Haruo Sugiyama, Masashi Gotoh, Hideo Takasu
  • Dimerized peptide
    Publication number: 20060217297
    Abstract: The present invention provides a novel tumor antigen peptide and its cancer vaccine, specifically, a peptide dimer wherein two peptide monomers consisting of 7-30 amino acids including at least one cysteine residue and being capable of producing a tumor antigen peptide are bound each other through a disulfide bond.
    Type: Application
    Filed: January 15, 2004
    Publication date: September 28, 2006
    Inventors: Haruo Sugiyama, Hideo Takasu, Fumio Samizo
  • Wt1 substitution pepides
    Publication number: 20060205667
    Abstract: Novel substituted type peptides of WT1 wherein the cysteine residue is substituted with a defined amino acid residue, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. Peptides which comprise an amino acid sequence of the formula: X—Y-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 4) wherein X represents Ser, Ala, Abu, Arg, Lys, Orn, Cit, Leu, Phe, or Asn, and Y represents Tyr or Met, and which has an activity to induce CTLs, polynucleotides encoding said peptides, cancer vaccines which comprise those peptides or polynucleotides as an active ingredient, and the like are disclosed.
    Type: Application
    Filed: September 19, 2003
    Publication date: September 14, 2006
    Inventors: Haruo Sugiyama, Masashi Gotoh, Hideo Takasu, Fumio Samizo, Naoto Kusunose, Masashi Nakatsuka